Agenus Inc
NASDAQ:AGEN
Agenus Inc
NASDAQ:AGEN
Price:
12.52 USD
-5.58%
Market Closed
Updated:
May 3, 2024
Agenus Inc
Cash from Financing Activities
|
Agenus Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Agenus Inc
NASDAQ:AGEN
|
Cash from Financing Activities
$119.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
17%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Agenus Inc's Cash from Financing Activities?
Cash from Financing Activities
119.9m
USD
119.9m
USD
Based on the financial report for Dec 31, 2023, Agenus Inc's Cash from Financing Activities amounts to 119.9m USD.
What is Agenus Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
17%
17%
Over the last year, the Cash from Financing Activities growth was 25%. The average annual Cash from Financing Activities growth rates for Agenus Inc have been -13% over the past three years , -1% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
